NZ Immuno-Oncology Research Review Issue 4

In this issue:

Atezolizumab vs. chemotherapy in urothelial carcinoma
The clinical immuno-oncology landscape
Response patterns in metastatic NSCLC during anti-PD-1/PD-L1 therapy
Endocrine dysfunction associated with immune checkpoint inhibitor regimens
Survival in checkpoint inhibitor recipients with advanced NSCLC
Nivolumab + ipilimumab for advanced melanoma
Pembrolizumab for advanced oesophageal carcinoma
Nivolumab + ipilimumab in metastatic RCC
Nivolumab vs. docetaxel in previously treated advanced NSCLC
Anti-PD1/PD-L1 response in NSCLC profiled with targeted NGS

Please login below to download this issue (PDF)